Humana Inc. (NYSE:HUM) Declares Quarterly Dividend of $0.89

Humana Inc. (NYSE:HUM) announced a quarterly dividend on Thursday, October 24th, RTT News reports. Investors of record on Tuesday, December 31st will be given a dividend of 0.885 per share by the insurance provider on Friday, January 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.37%.

Humana has raised its dividend payment by an average of 12.3% per year over the last three years. Humana has a dividend payout ratio of 17.9% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Humana to earn $19.70 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 18.0%.

Humana Stock Performance

HUM traded down $0.07 during trading on Thursday, hitting $258.58. The stock had a trading volume of 1,675,783 shares, compared to its average volume of 1,852,383. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana has a 12 month low of $213.31 and a 12 month high of $527.18. The company has a 50 day simple moving average of $310.28 and a 200-day simple moving average of $337.43. The firm has a market cap of $31.16 billion, a PE ratio of 16.10, a P/E/G ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the firm posted $8.94 EPS. The company’s revenue was up 10.4% on a year-over-year basis. Analysts expect that Humana will post 16.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HUM. TD Cowen downgraded shares of Humana from a “buy” rating to a “hold” rating and reduced their price target for the company from $402.00 to $261.00 in a report on Monday, October 7th. Piper Sandler downgraded Humana from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $392.00 to $274.00 in a research report on Thursday, October 3rd. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. KeyCorp assumed coverage on Humana in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research note on Tuesday, October 8th. One investment analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.